Lixte Biotechnology closed its acquisition of NOMAD Transportable Power Systems via merger, issuing 50,366.07 shares of Series D Convertible Preferred (convertible at $1.00) and 2,992,041 common shares at closing, with capacity for up to 50,500 preferred and roughly 3,000,005 common in total. An amendment updated fractional-share handling and the consideration schedule. Concurrently, Lixte signed a Registration Rights Agreement to register resales of the issued shares under specified timelines and secured Stockholder Support Agreements to back key post-merger approvals, including preferred conversion and board elections.
Agreement 1: Lixte Biotechnology Completes Merger With NOMAD; Issues 50.4K Series D Preferred and 3.0M Shares
- Agreement type: Merger Agreement and Amendment No. 1
- Counterparty: NOMAD Transportable Power Systems
- Signed / Effective: Jun 11 2026 / Jul 01 2026
- Duration / Termination: Until closing
- Reason: Transform business via acquisition of mobile power platform
Agreement 2: Lixte Grants Resale Rights to NOMAD Holders With Post-Approval Registration Timeline
- Agreement type: Registration Rights Agreement
- Counterparty: Holders of NOMAD common stock
- Signed / Effective: Jul 01 2026 / Jul 01 2026
- Duration / Termination: Until resale registration completed
- Reason: Provide liquidity to former NOMAD holders
Agreement 3: Lixte Secures Stockholder Support Commitments for Post-Merger Approvals
- Agreement type: Stockholder Support Agreement
- Counterparty: Supporting Stockholders of Lixte
- Signed / Effective: Jul 01 2026 / Jul 01 2026
- Duration / Termination: Until stockholder vote
- Reason: Secure votes for conversion and governance approvals
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.